Ambasilide

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 592767

CAS#: 83991-25-7

Description: Ambasilide is a Class III antiarrhythmic agent.

Chemical Structure

img
Ambasilide
CAS# 83991-25-7
Instruction

Theoretical Analysis

MedKoo Cat#: 592767
Name: Ambasilide
CAS#: 83991-25-7
Chemical Formula: C21H25N3O
Exact Mass: 335.20
Molecular Weight: 335.450
Elemental Analysis: C, 75.19; H, 7.51; N, 12.53; O, 4.77

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Ambasilide; Ambasilidum

IUPAC/Chemical Name: 3-(p-Aminobenzoyl)-7-benzyl-3,7-diazabicyclo(3.3.1)nonane

InChi Key: DLNAKYFPFYUBDR-UHFFFAOYSA-N

InChi Code: InChI=1S/C21H25N3O/c22-20-8-6-19(7-9-20)21(25)24-14-17-10-18(15-24)13-23(12-17)11-16-4-2-1-3-5-16/h1-9,17-18H,10-15,22H2

SMILES Code: O=C(N1CC(C2)CN(CC3=CC=CC=C3)CC2C1)C4=CC=C(N)C=C4

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 335.45 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Bosch RF, Milek IV, Popovic K, Mermi J, Mewis C, Kühlkamp V, Seipel L. Ambasilide prolongs the action potential and blocks multiple potassium currents in human atrium. J Cardiovasc Pharmacol. 1999 May;33(5):762-71. PubMed PMID: 10226864.

2: Koidl B, Flaschberger P, Schaffer P, Pelzmann B, Bernhart E, Mächler H, Rigler B. Effects of the class III antiarrhythmic drug ambasilide on outward currents in human atrial myocytes. Naunyn Schmiedebergs Arch Pharmacol. 1996 Jan;353(2):226-32. PubMed PMID: 8717164.

3: Baláti B, Iost N, Simon J, Varró A, Papp JG. Analysis of the electrophysiological effects of ambasilide, a new antiarrhythmic agent, in canine isolated ventricular muscle and purkinje fibers. Gen Pharmacol. 2000 Feb;34(2):85-93. PubMed PMID: 10974415.

4: Kijtawornrat A, Hamlin RL, Hamlin DM. Effects of ambasilide in isolated perfused guinea pig heart: use dependence. Cardiovasc Toxicol. 2005;5(1):53-62. PubMed PMID: 15738585.

5: Walker BD, Singleton CB, Tie H, Bursill JA, Wyse KR, Valenzuela SM, Breit SN, Campbell TJ. Comparative effects of azimilide and ambasilide on the human ether-a-go-go-related gene (HERG) potassium channel. Cardiovasc Res. 2000 Oct;48(1):44-58. PubMed PMID: 11033107.

6: Schreieck J, Wang Y, Gjini V, Korth M, Zrenner B, Schömig A, Schmitt C. Differential effect of beta-adrenergic stimulation on the frequency-dependent electrophysiologic actions of the new class III antiarrhythmics dofetilide, ambasilide, and chromanol 293B. J Cardiovasc Electrophysiol. 1997 Dec;8(12):1420-30. PubMed PMID: 9436780.

7: Villa S, Barlocco D, Cignarella G, Papp GJ, Baláti B, Takács J, Varró A, Borosy A, Keserû K, Mátyus P. 3,8-diazabicyclo--[3.2.1]-octane derivatives as analogues of ambasilide, a Class III antiarrhythmic agent. Eur J Med Chem. 2001 Jun;36(6):495-506. PubMed PMID: 11525840.

8: Stramba-Badiale M, Pessano P, Kirchengast M, Schwartz PJ. Effects of the potassium channel blocking agent ambasilide on ventricular arrhythmias induced by acute myocardial ischemia and sympathetic activation. Am Heart J. 1995 Mar;129(3):549-56. PubMed PMID: 7872187.

9: Takanaka C, Sarma JS, Singh BN. Electrophysiologic effects of ambasilide (LU 47110), a novel class III antiarrhythmic agent, on the properties of isolated rabbit and canine cardiac muscle. J Cardiovasc Pharmacol. 1992 Feb;19(2):290-8. PubMed PMID: 1376799.

10: Wang J, Feng J, Nattel S. Class III antiarrhythmic drug action in experimental atrial fibrillation. Differences in reverse use dependence and effectiveness between d-sotalol and the new antiarrhythmic drug ambasilide. Circulation. 1994 Oct;90(4):2032-40. PubMed PMID: 7923691.

11: Yue L, Feng JL, Wang Z, Nattel S. Effects of ambasilide, quinidine, flecainide and verapamil on ultra-rapid delayed rectifier potassium currents in canine atrial myocytes. Cardiovasc Res. 2000 Apr;46(1):151-61. PubMed PMID: 10727663.

12: Zhang ZH, Follmer CH, Sarma JS, Chen F, Singh BN. Effect of ambasilide, a new class III agent, on plateau currents in isolated guinea pig ventricular myocytes: block of delayed outward potassium current. J Pharmacol Exp Ther. 1992 Oct;263(1):40-8. PubMed PMID: 1403801.

13: Feng J, Wang Z, Li GR, Nattel S. Effects of class III antiarrhythmic drugs on transient outward and ultra-rapid delayed rectifier currents in human atrial myocytes. J Pharmacol Exp Ther. 1997 Apr;281(1):384-92. PubMed PMID: 9103521.

14: Weyerbrock S, Schreieck J, Karch M, Overbeck M, Meisner H, Kemkes B, Schömig A, Schmitt C. Rate-independent effects of the new class III antiarrhythmic agent ambasilide on transmembrane action potentials in human ventricular endomyocardium. J Cardiovasc Pharmacol. 1997 Nov;30(5):571-5. PubMed PMID: 9388038.

15: Zaza A, Malfatto G, Schwartz PJ. Effects on atrial repolarization of the interaction between K+ channel blockers and muscarinic receptor stimulation. J Pharmacol Exp Ther. 1995 Jun;273(3):1095-104. PubMed PMID: 7791080.

16: Gjini V, Korth M, Schreieck J, Weyerbrock S, Schömig A, Schmitt C. Differential class III antiarrhythmic effects of ambasilide and dofetilide at different extracellular potassium and pacing frequencies. J Cardiovasc Pharmacol. 1996 Aug;28(2):314-20. PubMed PMID: 8856489.

17: Mehdirad AA, Carnes CA, Nelson SD. The influence of specific and nonspecific potassium current blockade on the defibrillation energy requirement of biphasic shock. Pacing Clin Electrophysiol. 1999 Jan;22(1 Pt 2):147-51. PubMed PMID: 9990620.

18: Capucci A, Aschieri D, Villani GQ, Piepoli MF. Clinical potential of emerging antiarrhythmic agents. Drugs R D. 1999 Apr;1(4):279-90. Review. PubMed PMID: 10566046.

19: Lombardi F, Terranova P. Pharmacological treatment of atrial fibrillation: mechanisms of action and efficacy of class III drugs. Curr Med Chem. 2006;13(14):1635-53. Review. PubMed PMID: 16787210.

20: Dorian P. Mechanisms of action of class III agents and their clinical relevance. Europace. 2000 Jul;1 Suppl C:C6-9. Review. PubMed PMID: 11220521.